Evidence map›Paper›PMID 27011289›Full record

ReviewExpert opinion on biological therapy2016

Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases.

Antoine Monsel, Ying-Gang Zhu, Varun Gudapati, Hyungsun Lim, Jae W Lee

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on biological therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05191381 (Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19), which is not on this map. Cited by 108 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05191381 recruitingnot on this mapstarted 2021, after this paper: background citation

Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19

Typeobservational_patient_registrySponsorUniversity of UlmRan2021 to 2026Enrolled40ConditionsCOVID-19, Critical Illness, Hypercytokinemia, Lung FibrosisArmsApplication of exosomes in a whole blood assay
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Antoine Monsela Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care , La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, University Pierre and Marie Curie (UPMC) Univ Paris 06 , Paris , France.
Ying-Gang Zhub Department of Pulmonary Disease , Huadong Hospital, Fudan University , Shanghai , China.
Varun Gudapatic Department of Anesthesiology , University of California San Francisco , San Francisco , CA , USA.
Hyungsun Limc Department of Anesthesiology , University of California San Francisco , San Francisco , CA , USA.
Jae W Leec Department of Anesthesiology , University of California San Francisco , San Francisco , CA , USA.

Funding

Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung InjuryR01HL113022 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, JAE WOO · 2012 to 2020
$4.1M
NHLBI NIH HHS R01 HL113022
6 · The paper itself

Abstract

introductionAcute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. Despite extensive research into its pathophysiology, mortality remains high. No effective pharmacotherapy exists. Based largely on numerous preclinical studies, administration of mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury holds great promise, and clinical trials are currently underway. However, concern for the use of stem cells, specifically the risk of iatrogenic tumor formation, remains unresolved. Accumulating evidence now suggest that novel cell-free therapies including MSC-derived conditioned medium and extracellular vesicles released from MSCs might constitute compelling alternatives. AREAS COVERED: The current review summarizes the preclinical studies testing MSC conditioned medium and/or MSC extracellular vesicles as treatment for acute lung injury and other inflammatory lung diseases. EXPERT OPINION: While certain logistical obstacles limit the clinical applications of MSC conditioned medium such as the volume required for treatment, the therapeutic application of MSC extracellular vesicles remains promising, primarily due to ability of extracellular vesicles to maintain the functional phenotype of the parent cell. However, utilization of MSC extracellular vesicles will require large-scale production and standardization concerning identification, characterization and quantification.

Indexed as

Acute Lung InjuryAnimalsCulture Media, ConditionedExtracellular VesiclesHumansInflammationLung DiseasesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationCulture Media, ConditionedAcute lung injuryacute respiratory distress syndromeexosomesextracellular vesiclesmesenchymal stem cellsmicrovesicles

Identifiers

PMID27011289
PMCPMC5280876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.